Case Report
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Mar 24, 2025; 16(3): 99527
Published online Mar 24, 2025. doi: 10.5306/wjco.v16.i3.99527
Efficacy of disitamab vedotin-containing therapy in metastatic colorectal cancer: A case report
Hu-Cheng Yan, Yan Liu, You Feng, Jun-Ming Li, Lei-Ming Sheng, Xin Chen, Yu-Ping Xie, Na Li
Hu-Cheng Yan, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, Sichuan Province, China
Hu-Cheng Yan, Yan Liu, You Feng, Lei-Ming Sheng, Xin Chen, Yu-Ping Xie, Na Li, Department of Oncology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Jun-Ming Li, Department of Radiology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Li N constructed this work and revised the manuscript; Yan HC contributed to reviewing and editing the manuscript; Li JM, Liu Y, Sheng LM, Chen X, and Xie YP provided valuable recommendations; Feng Y and Sheng LM participated in data analysis; and all authors have read and approved the final manuscript.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Na Li, PhD, Department of Oncology, West China School of Public Health and West China Fourth Hospital, Sichuan University, No. 18 Section 3, Renmin South Road, Chengdu 610041, Sichuan Province, China. 281422934@qq.com
Received: July 24, 2024
Revised: November 10, 2024
Accepted: December 30, 2024
Published online: March 24, 2025
Processing time: 180 Days and 21.2 Hours
Core Tip

Core Tip: Colorectal cancer (CRC) is a leading cause of cancer-related mortality. In cases of metastatic CRC (mCRC) that is resistant to conventional chemotherapy, human epidermal growth factor receptor 2 (HER2)-targeted therapies have shown promise. We describe a 69-year-old woman with HER2-overexpressing mCRC, featuring an NRAS p.G12V mutation and microsatellite stability, who achieved an excellent response to disitamab vedotin treatment. This case is notable as it is the first recorded observation of a notable clinical response to anti-HER2 therapy in an mCRC patient with HER2 overexpression and an NRAS p.G12V mutation.